The estimated Net Worth of Bertil Lindmark is at least $820 ezer dollars as of 22 March 2022. Prof Lindmark owns over 14,604 units of Galecto stock worth over $217,844 and over the last 4 years he sold GLTO stock worth over $0. In addition, he makes $602,626 as Chief Medical Officer at Galecto.
Prof has made over 2 trades of the Galecto stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 14,604 units of GLTO stock worth $31,545 on 22 March 2022.
The largest trade he's ever made was buying 14,604 units of Galecto stock on 22 March 2022 worth over $31,545. On average, Prof trades about 3,321 units every 53 days since 2021. As of 22 March 2022 he still owns at least 16,604 units of Galecto stock.
You can see the complete history of Prof Lindmark stock trades at the bottom of the page.
Prof. Bertil Lindmark M.D., Ph.D. is the Chief Medical Officer at Galecto.
As the Chief Medical Officer of Galecto, the total compensation of Prof D at Galecto is $602,626. There are 1 executives at Galecto getting paid more, with Dr. Hans T. Schambye having the highest compensation of $644,982.
Prof D is 66, he's been the Chief Medical Officer of Galecto since . There are no older and 4 younger executives at Galecto.
Bertil's mailing address filed with the SEC is C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N, G7, DK-2200.
Over the last 4 years, insiders at Galecto have traded over $2,298,261 worth of Galecto stock and bought 1,911,769 units worth $28,139,830 . The most active insiders traders include Holdings A/S Novo, Chau Quang Khuong és Carl Goldfischer. On average, Galecto executives and independent directors trade stock every 46 days with the average trade being worth of $2,037,418. The most recent stock trade was executed by Advisors Llc Orbi Med Genes... on 15 August 2023, trading 822,680 units of GLTO stock currently worth $617,010.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Galecto executives and other stock owners filed with the SEC include: